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Background: Rectal cancer is one of the most common cancers in the world. Early detection and early therapy are
important for the control of death caused by rectal cancer. The present study aims to investigate the genomic
alterations in rectal adenoma and carcinoma.
Methods: We detected the genomic changes of 8 rectal adenomas and 8 carcinomas using array CGH. Then 14
genes were selected for analyzing the expression between rectal tumor and paracancerous normal tissues as well
as from adenoma to carcinoma by real-time PCR. The expression of GPNMB and DIS3 were further investigated in
rectal adenoma and carcinoma tissues by immunohistochemistry.
Results: We indentified ten gains and 22 losses in rectal adenoma, and found 25 gains and 14 losses in carcinoma.
Gains of 7p21.3-p15.3, 7q22.3-q32.1, 13q13.1-q14.11, 13q21.1-q32.1, 13q32.2-q34, 20p11.21 and 20q11.23-q12 and
losses of 17p13.1-p11.2, 18p11.32-p11.21 and 18q11.1-q11.2 were shared by both rectal adenoma and carcinoma.
Gains of 1q, 6p21.33-p21.31 and losses of 10p14-p11.21, 14q12-q21.1, 14q22.1-q24.3, 14q31.3-q32.1, 14q32.2-q32.32,
15q15.1-q21.1, 15q22.31 and 15q25.1-q25.2 were only detected in carcinoma but not in adenoma. Copy number
and mRNA expression of EFNA1 increased from rectal adenoma to carcinoma. C13orf27 and PMEPA1 with
increased copy number in both adenoma and carcinoma were over expressed in rectal cancer tissues. Protein and
mRNA expression of GPNMB was significantly higher in cancer tissues than rectal adenoma tissues.
Conclusion: Our data may help to identify the driving genes involved in the adenoma-carcinoma progression.Background
Rectal cancer is the 5th leading cause of cancer-related
death and its incidence is increasing at a rate of 4.2% per
year in China [1]. Early detection and early therapy are
important for the control of death caused by rectal cancer.
The majority of epithelial cancers arise through a step-
wise progression from normal cells, through dysplasia,
into malignant cells that have invasive and metastatic
potential. The classic example of this process is the colo-
rectal adenoma to carcinoma progression [2,3]. Genomic
aberrations are found frequently in cancers and are
believed to contribute to initiation and progression of* Correspondence: wangmr2015@cicams.ac.cn; zhangyu909@126.com
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reproduction in any medium, provided the orcancer by deletion-induced down-expression of tumor
suppressor genes or amplification and activation of
oncogenes. In colorectal cancer the most frequent
chromosomal aberrations were gains at 7p, 7q, 8q, 13q,
and 20q and losses of 1p, 4p, 4q, 5q, 8p, 14q, 15q, 17p
and 18q [4-9]. In particular, 8q, 13q and 20q gains and
8p, 15q and 18q losses are linked with colorectal aden-
oma to carcinoma progression. However, most of pub-
lished reports are focused on colon cancer. Little
information is available concerning the genomic aberra-
tions of rectal carcinoma, especially DNA copy number
changes in the progression from adenoma to tumor.
In the present study, we investigated the genomic
aberrations of rectal adenoma and carcinoma by
oligonucleotide-based array CGH, and identified common
and different alterated chromosome regions between rec-
tal adenoma and carcinoma. Then the expression of 15. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by real-time PCR or immunohistochemistry.
Methods
Patients and samples
Biopsy tissues from 22 rectal adenoma patients and 36
rectal carcinoma patients were collected by the Depart-
ment of Endoscopy, Cancer Hospital, Peking Union Med-
ical College and Chinese Academy of Medical Sciences,
Beijing, China. Biopsy samples were obtained by colonos-
copy and stored at −80°C. Definitive pathological result
from a biopsy was obtained at a later clinical course. An
experienced pathologist confirmed that normal cell con-
tent of all the samples was less than 40% by HE staining.
All the samples used in this study were residual specimens
after diagnosis sampling. And all patients signed separate
informed consent forms for sampling and research. The
clinicopathological characteristics of the patients in array
CGH assay are summarized in Table 1.
Genomic DNA extraction and array-based CGH
Genomic DNA was isolated from tumor tissues using
the Qiagen DNeasy Blood & Tissue Kit as described by
the manufacturer (Qiagen, Hilden, Germany).
Array CGH experiments were performed using standard
Agilent protocols (Agilent Technologies, Santa Clara, CA).
Commercial human genomic DNA (PROMEGA, Warring-
ton, UK) was used as reference. For each CGH
hybridization, 500 ng of reference genomic DNA and the
same amount of tumor DNA were digested with Alu I and
RSA I restriction enzyme (PROMEGA, Warrington, UK).Table 1 Clinical Characteristics of 16 Patients Studied by
Array CGH
Case No. Sex Age Type Location
1 F 52 Adenoma Rectum
2 F 49 Adenoma Rectum
3 M 75 Adenoma Rectum
4 M 47 Adenoma Rectum
5 M 57 Adenoma Rectum
6 F 61 Adenoma Rectum
7 M 69 Adenoma Rectum
8 F 75 Adenoma Rectum
9 M 69 Carcinoma Rectum
10 M 61 Carcinoma Rectum
11 F 70 Carcinoma Rectum
12 F 73 Carcinoma Rectum
13 M 42 Carcinoma Rectum
14 M 32 Carcinoma Rectum
15 F 31 Carcinoma Rectum
16 M 66 Carcinoma RectumThe digested reference DNA fragments were labeled with
cyanine-3 dUTP and the tumor DNA with cyanine-5 dUTP
(Agilent Technologies, Santa Clara, CA). After clean-up,
reference and tumor DNA probes were mixed and hybri-
dized onto Agilent 44K human genome CGH microarray
(Agilent) for 40 h. Washing, scanning and data extraction
procedures were performed following standard protocols.




Microarray data were analyzed using Agilent Genomic
Workbench (Agilent Technologies, Santa Clara, CA) and
MD-SeeGH (www.flintbox.ca). The Aberration Detection
Method 2 algorithm with threshold at 6 (Agilent Genomic
Workbench) was applied to identify common genomic
aberrations. Mean Log2ratio of all probes in a chromosome
region between 0.125 and 0.5 was classified as genomic
gain, > 0.5 as high-level DNA amplification, < −0.125 as
hemizygous loss, and < −0.5 as homozygous deletion. Min-
imal regions of gains or losses in our study defined as the
smallest overlapping aberrant chromosomal regions iden-
tified by Agilent Genomic Workbench. Frequency plot
comparison method (MD-SeeGH) was used to compare
frequency of DNA copy number changes between rectal
adenoma and carcinoma.
Total RNA extraction and real-time PCR
Total RNA was isolated from tissues using the RNeasy
Mini Kit as described by the manufacturer (Qiagen, Hil-
den, Germany).
The PCR reactions were performed in a total volume
of 20 μl, including 10 μl of 2 X SYBR W Green PCR
Master Mix (Applied Biosystems, Warrington, UK), 2 μl
of cDNA (5 ng/μl), 1 μl of primer mix (10 μM each).
The PCR amplification and detection were carried out in
a 7300 Real Time PCR System (Applied Biosystems) for
45 cycles, each with 15 s at 95 °C, 1 min at 60 °C, and
initial denaturation with 10 min at 95 °C. The relative
gene expression was calculated using the comparative
CT Method [11]. The copy number of the target gene
normalized to an endogenous reference (GAPDH), and
relative to calibrator was given by the formula 2 −ΔΔCt.
ΔCT was calculated by subtracting the average GAPDH
CT from the average CT of the gene of interest. The
ratio defines the level of relative expression of the target
gene to that of GAPDH.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded specimens of rectal aden-
oma and carcinoma were detected in immunohistochemistry
assay. Tissues of each case were repeated for three times.
The slides were deparaffinized, rehydrated, immersed in
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rate buffer (pH 6) for 25 min at 95°C, and cooled for 60
min at room temperature. The slides were blocked by 10%
normal goat serum for 30 min at 37°C and then incubated
with rabbit polyclonal antibody against DIS3 (PTGLab),
rabbit polyclonal antibody against GPNMB (PTGLab) over-
night at 4°C. After being washed with PBS, the slides were
incubated with biotinylated secondary antibody (diluted
1:100) for 30 min at 37°C, followed by streptavidin-
peroxidase (1:100 dilution) incubation for 30 min at 37°
C. Immunolabeling was visualized with a mixture of 3,3'-
diaminobenzidine solution. Counterstaining was carried
out with hematoxylin.Figure 1 Genome-wide frequency plot of rectal adenoma (A) and ade
gain; Line on the left of 0%-axis: loss.Expression level was determined on the basis of staining
intensity and percentage of immunoreactive cells. Nega-
tive expression (score = 0) was no or faint staining, or
moderate to strong staining in <25% of cells. Weak ex-
pression (score = 1) was a moderate or strong staining
in 25% to 50% of cells. And strong expression (score = 2)
was > 50% of the cells with strong staining. Weak expres-
sion and strong expression defined as positive staining.
Statistical analysis
Statistical analyses were conducted using the Student’s t-
test and performed with the statistical software SPSS
15.0. The differences were judged as statisticallynocarcinoma (B) in array CGH assay. Line on the right of 0%-axis:
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were <.05.
Results
Recurrent copy number alterations in rectal adenoma and
carcinoma detected by array CGH
Seven out of eight adenomas and all of carcinomas had
genomic aberrations. More alterations were observed in
patients of rectal cancer than adenoma, and the num-
bers of changes were 39.13±20.48 and 14.3±6.164, re-
spectively (Additional file 1: Figure S1). Array CGHTable 2 Genomic Gains in Rectal Adenoma and Adenocarcino






























Note: The number of rectal adenoma and adenocarcinoma in Array CGH study areresults showed that the most frequent copy number
alterations in rectal adenoma were gains of 7p21.3-
p15.3 and 20p12.3-p11.21 and losses of 5q13.2, 7q11.23,
11q13.1-q14.1, 17q25.1 and 19p13.3-p13.11 (Figure 1A,
Tables 2 and 3). And the most common genetic aberra-
tions in rectal carcinoma were gains of 7p21.3-p15.3,
7p15.3-p14.1, 7p14.1-p13, 7p13-p11.2, 13q13.1-q14.11,
13q21.1-q32.1, 13q32.1-q34, 20p11.21, 20q11.23-q12
and 20q13.2-q13.33 and losses of 17p13.1-p11.2,











150819451 150852905 3 3
183720174 197184608 157 3
204180950 214439909 173 3
33503866 45681293 165 3
30737615 33655570 151 4
848 2
119 4 7671318 23172047 142 5
23821348 39813908 231 5
40099046 44497196 64 5
44890654 55242365 111 5
42 2
87207024 97321855 144 4
245 2 105253205 127519635 260 4
59565778 61340797 21 3
128816904 133653633 42 3
7058096 31463899 251 4
192958 2278596 76 4
66917525 67689856 30 4
337 2
139 2
50568352 51486634 34 4
354 2
909 2 32490193 39679219 79 7
52774228 94079000 275 7
100091512 114022929 148 7
9800520 19631574 473 3
43396893 55615310 550 3
189 3 22510206 23380542 15 8
275 2 35467169 41087006 78 7
52017030 62323759 215 7
both 8 cases.
Table 3 Genomic Losses in Rectal Adenoma and Adenocarcinoma
Chromosome Region Rectal adenoma Rectal adenocarcinoma








1p36.23-p36.22 7804415 11633739 82 3
1p36.22-p36.13 12600054 16167534 41 3
1p36.12-p35.3 21802142 29525663 226 3
1q21.2-q21.3 148163183 149505863 60 2
1q21.3-q23.1 151880217 155031244 154 2
4q12 55913547 57653302 38 2
5p15.33-p12 260981 45865412 433 2
5q13.2 68434643 68900029 18 3
7p22.2-p22.1 4298590 6547570 42 2
7q11.23 72003839 75977276 77 3
7q22.1 99538250 101895994 79 2
8q22.2-q24.3 100781187 143914353 448 2
8q24.3 143914353 146250824 75 2
9q34.11 130111425 132321365 64 2
10p14-p11.21 11825924 35645512 315 3
11p15.2-p11.12 14750051 50638829 468 2
11q13.1-q14.1 63802950 80046693 442 4
12q24.23-q24.33 116956235 132193660 257 2
14q12-q21.1 30209271 38927323 130 3
14q22.1-q24.3 48874529 77750644 544 3
14q31.3-q32.1 87763614 93260389 110 3
14q32.2-q32.32 99254905 102592287 70 3
15q15.1-q21.1 38653893 42843706 119 3
15q22.31 61519869 64628895 74 3
15q25.1-q25.2 76206143 79967204 77 3
17p13.1-p11.2 84287 21386319 606 2 8327645 20974722 266 4
17q25.1 70528777 71603516 61 3
18p11.32-p11.21 170229 13875315 173 2 2580000 13752309 137 5
18q11.1-q11.2 16904187 76018409 684 2 16976046 20313378 51 4
19p13.3-p13.11 1432408 19699544 795 4
19q13.11-q13.43 37554715 63672832 1114 2
20q13.33 60039825 62320720 85 2
22q13.1 37689058 37715431 3 2
Note: The number of rectal adenoma and adenocarcinoma in Array CGH study are both 8 cases.
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and carcinoma
By comparing the genomic aberrations of rectal aden-
oma and carcinoma, we found that gains of 7p21.3-
p15.3, 7q22.3-q32.1, 13q13.1-q14.11, 13q21.1-q32.1,
13q32.3-q34, 20p11.21 and 20q11.23-q12 and losses of
17p13.1-p11.2, 18p11.32-p11.21, and 18q11.1-q11.2 were
shared by rectal adenoma and carcinoma. However,
gains of 1q, 6p21.33-p21.31 and losses of 10p14-p11.21,14q12-q21.1, 14q22.1-q24.3, 14q31.3-q32.1, 14q32.2-
q32.32, 15q15.1-q21.1, 15q22.31 and 15q25.1-q25.2 were
detected in carcinoma but not in adenoma (Figure 2,
Tables 2 and 3).
Candidate target genes of interesting gains and losses
Further, we selected 14 genes of 1q, 6p, 7p, 13q, 18q
and 20q to analyze the mRNA expression by real-
time PCR (Table 4). Array CGH found that copy
Figure 2 Frequency plot comparison of rectal adenoma and carcinoma. Red: carcinoma; green: adenoma; yellow: shared by both. The
presentation is per array probe; gains and losses are represented by the colors on the right and left, respectively. Vertical blue line represents
100% of the samples. Brown and blue arrows highlight the changed chromosomal areas that were common or distinct between rectal adenoma
and carcinoma, respectively.
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(13q32.1), C13orf27 (13q32.2-q34), PMEPA1
(20q13.31), PHACTR3 (20q13.32) and decrease of
SMAD4 (18q21.2), BCL2 (18q21.33) occurred in both
rectal adenoma and carcinoma. Our real-time PCR
results showed that C13orf27 and PMEPA1 were
overexpressed in rectal cancer tissues comparing with
paracancerous normal tissues. BCL2 and SMAD4
were underexpressed in tumor tissue (Figure 3A).
And the expression level of C13orf27 and GPNMB
was significantly higher in cancer tissues than rectal
















GPNMB GTCACTGTGATCTCCCTCTTGGCopy number increase of EFNA1 (1q22), PTGS2
(1q31.1), KDM5B (1q32.1), ESRRG (1q41), KIFC1
(6p21.32), PBX2 (6p21.32) and SOX4 (6p22.3) were only
detected in rectal cancer in array CGH. Among them,
EFNA1 had increased expression in carcinoma com-
pared with adenoma, and KIFC1 had an upward trend
but not significant in statistical analysis (Figure 4A). Of
these genes KIFC1 and SOX4 were also significantly
overexpressed in rectal tumor tissues than paracancer-
ous tissues (Figure 4B).
We also analyzed the protein expression of GPNMB
















Figure 3 Expression of genes which were located on the common aberrant chromosomal regions in rectal adenoma and carcinoma. N:
paracancerous normal tissues; T: rectal cancer tissues.
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DIS3 had no expression. In twenty rectal cancer tissues,
GPNMB and DIS3 were positively stained in six and five
cases, respectively (Figure 5).
Discussion
In the past decades, a number of genomic changes
were found in colorectal adenoma and carcinoma,
but the target genes are limited and molecular mech-
anism of adenoma to carcinoma progression is still
unknown.
Previous studies found that 8q, 13q and 20q gains and
8p, 15q and 18q losses are linked with colorectal aden-
oma to carcinoma progression [4-9]. Our study nar-
rowed down the gain regions to 13q13.1-q14.11,
13q21.1-q32.1, 13q32.2-q34 and 20q11.23-q12 and the
loss regions to 18q11.2. Furthermore, gains of 7p21.3-
p15.3 and 7q22.3-q32.1 and losses of 17p13.1-p11.2,
18p11.32-p11.21 were also found in both rectal adenoma
and carcinoma.
Our study also showed that some genomic aberrations
were present in rectal tumor but not in adenoma. Theyare gains of 1q and 6p21.33 and losses of 10p14-p11.21,
14q12-q21.1, 14q22.1-q24.3, 14q31.3-q32.1, 14q32.2-
q32.32, 15q15.1-q21.1, 15q22.31 and 15q25.1-q25.2.
These aberrations occurred at the later stages of rectal
carcinogenesis, and may contribute the progression from
adenoma to carcinoma.
Identifying the candidate targets underlying the gen-
omic aberrations was important for understanding the
mechanism of carcinogenesis. Carvalho et al. found that
the overexpressions of C20orf24, AURKA, RNPC1,
TH1L, ADRM1, C20orf20 and TCRL5 in carcinomas
compared with adenomas were correlated with 20q gain
[4]. Habermann et al. showed that copy number changes
of 7q, 8p, 8q, 13q, 18p, 18q, 20p and 20q deregulated
the average expression levels of the genes on these
chromosome arms [12]. However, most of samples
detected in these reports were colon cancer which had
some different genomic aberrations compared with rec-
tal cancer [13], expression-dysregulated genes in the car-
cinogenesis of rectum were still limited. By literature
analyses, we selected 14 genes to compare their expres-
sion between in tumor and paracancerous tissues or
Figure 4 Expression of genes which were located on the distinct aberrant chromosomal regions in rectal adenoma and carcinoma.
N: paracancerous normal tissues; T: rectal cancer tissues.
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them, copy number and mRNA expression of EFNA1
increased from rectal adenoma to carcinoma, and
C13orf27 and PMEPA1 with gains in both adenoma
and carcinoma were overexpressed in rectal cancer tis-
sues. These results revealed that copy number increase
maybe the reason of expression up-regulation. Interest-
ingly, both mRNA and protein expression of GPNMB
was higher in cancer tissues than rectal adenoma
tissues.
GPNMB is a type I transmembrane protein and over-
expressed in several malignant human tissues relative to
the corresponding normal tissues. Ectopic overexpres-
sion of GPNMB/osteoactivin can promote the metastasis
and invasion of glioma, breast and hepatocellular carcin-
oma [14-17]. EFNA1 was overexpressed in hepatocellu-
lar carcinoma and can inhibit growth of malignant
mesothelioma by phosphorylating EPHA2 [18,19].
C13orf27 was overexpressed in rectal tumor in our
study, but the function of C13orf27 was unknown.
PMEPA1 was also identified in our study, which is
mapped to 20q13.3 is a TGF-beta inducible gene and
encodes a NEDD4 E3 ubiguitin ligase binding protein.PMEPA1 is over-expressed in prostate, breast, renal cell,
stomach and rectal carcinomas [20-22]. But little is
known about the function of PMEPA1, Further study
should be conducted to investigate the roles of the above
genes in human colorectal cancer.
Loss of 18q is a common event in colorectal cancer,
and 18q deletion and loss of SMAD4 expression are
associated with liver metastasis. In colorectal cancer,
patients with reduced SMAD4 expression frequently
presented an unfavorable survival because of liver me-
tastasis [23-26]. High expression level of SMAD4
reflected significantly longer overall and disease-free sur-
vival time than low expression level [27]. Bixiang et al.
found that transgenic expression of SMAD4 can signifi-
cantly reduce the oncogenic potential of MC38 and
SW620 cells [28]. Our study confirmed the decreased
expression of SMAD4 in rectal cancer.
In summary, we identified EFNA1 (1q), C13orf27
(13q), PMEPA1 (20q), GPNMB (7q) as candidate driving
genes of genomic aberrations in rectal cancer. Further
study was needed to reveal the mechanisms by which
these genes may be involved in the carcinogenesis of the
rectum.
Figure 5 Expression of GPNMB and DIS3 by immunohistochemistry assay.
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Our data provide detailed information on genomic
aberrations present in rectal adenoma or carcinoma, es-
pecially both in two groups or only in rectal cancer.
Real-time PCR and immunohistochemistry assay selected
EFNA1, C13orf27, PMEPA1 and GPNMB as candidate
amplification targets. Our results may help to identify
the driving genes involved in the adenoma-carcinoma
progression.Additional file
Additional file 1: Figure S1. Comparison of rectal adenoma and
carcinoma in number of genomic aberrations.Competing interests
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